Already approved BCMA-targeting chimeric antigen receptor T-cell therapeutic Abecma (idecabtagene vicleucel) from Bristol Myers Squibb Company and bluebird bio has an eight-month head start over Janssen Pharmaceutical Cos. and Legend Biotech Corp.’s pending ciltacabtagene autoleucel (cilta-cel), but updated pivotal trial data for cilta-cel show response rates that could give the runner-up an advantage in the multiple myeloma market.
Janssen and Legend’s B-cell maturation antigen (BCMA)-targeting CAR-T therapy cilta-cel is under priority review at the US Food and Drug...